Name of the Medicinal Product

Trisenox is indicated for induction of remission and
consolidation in adult patients with relapsed/refactory acute promyelocytic
leukaemia (APL), characertised by the presence trisenox
of the t(15;17) translocation and/or the presence of the Pro-Myelocytic
Leukaemia/Retinoic-Acid Receptor-alpha (PML/RAR-alpha) gene. Previous
treatment should have included a retinoid and trisenox
chemotherapy.

The response rate of other acute myelogenous leukaemia subtypes to trisenox
has not been examined.

Active Substance
Arsenic trioxide

International Nonproprietary Name or Common Name
Arsenic trioxide

Pharmaco-therapeutic Group
Other antioneoplastic agents

ATC Code
LO1XX27

Therapeutic Indication